ASX Announcement

FURTHER MAYNE PHARMA AGM UPDATE – WITHDRAWAL OF DR BRETT WELLS DIRECTOR RESOLUTION

17 November 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX:MYX) advises that Dr Brett Wells has requested the Company to withdraw resolution 4 (Dr Wells' election resolution) of the notice of meeting for Mayne Pharma's Annual General Meeting to be held on Friday, 20 November 2026 (AGM) as a result of Mayne Pharma's announcement today regarding the execution of a Scheme Implementation Deed (SID) with Gedeon Richter Plc.

Accordingly, resolution 4 of the AGM is withdrawn and will not be put to shareholders.

All other items of business set out in the notice of meeting will proceed as notified.

Click here to view this announcement on Mayne Pharma's Investor Hub.

- ENDS -

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Board Chair.

Follow us on LinkedIn

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.